文献速递临床试验与 GCP基础与转化研究

高剂量静脉维生素C对严重烧伤患者死亡率及器官功能障碍的影响:VICTORY随机临床试验

High-Dose Intravenous Vitamin C and Mortality and Organ Dysfunction in Severe Burn Injury: The VICTORY Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-01-01

VICTORY为随机双盲安慰剂对照3期试验,纳入238例烧伤面积≥20%需植皮的成人患者,比较静脉维生素C(50 mg/kg每6小时共96小时)与安慰剂。因无效/危害预设界值被提前终止;维生素C组28天死亡率和复合终点事件数值更高,提示可能有害。

要点

  • 严重烧伤患者中高剂量静脉维生素C未改善28天死亡率与持续器官功能障碍复合终点。
  • 维生素C组28天死亡率15.0% vs 7.6%,校正RR 1.96(95%CI 1.32-2.90;P=.001)。
  • 因跨越预设无效/危害界值,试验在首次期中分析后提前终止。

核心结论

  • 在严重烧伤患者中,高剂量静脉维生素C未降低28天死亡率与持续器官功能障碍,且可能有害。

研究设计与样本

  • 随机、双盲、安慰剂对照3期试验,在北美、中美、南美、欧洲和亚洲24个烧伤中心开展。
  • 纳入年龄≥18岁、深二度/三度烧伤面积≥20%总体表面积且需植皮的成人患者,2020年8月18日至2025年9月12日入组。
  • 238例患者按1:1随机接受静脉维生素C(50 mg/kg每6小时共96小时)或匹配安慰剂;平均年龄48.9岁(SD 19.1),79%男性,平均烧伤面积37.0%(SD 14.6%)。

主要发现

  • 主要复合终点(28天死亡率与持续器官功能障碍)在维生素C组49例(40.8%)、安慰剂组35例(29.7%),校正RR 1.28(95%CI 0.99-1.65;P=.06)。
  • 90天内出院存活时间未改善,校正亚分布风险比0.85(95%CI 0.62-1.16;P=.31)。
  • 28天死亡率维生素C组15.0% vs 安慰剂组7.6%,校正RR 1.96(95%CI 1.32-2.90;P=.001)。
  • 住院死亡率维生素C组23.3% vs 安慰剂组16.1%,校正RR 1.44(95%CI 1.03-2.00;P=.03)。

关键数值与推荐

  • 主要终点为28天死亡率与持续器官功能障碍的复合终点,后者定义为第28天依赖机械通气、肾脏替代治疗或血管活性药/正性肌力药支持。
  • 试验在首次预设期中分析因无效/危害而提前终止。

临床怎么用

  • 严重烧伤患者不应常规使用高剂量静脉维生素C以改善死亡率或器官功能障碍。

局限性

  • 试验因无效/危害提前终止,样本量238例,结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Severe burn injury triggers systemic inflammation that can lead to multiple organ dysfunctions and death. High-dose intravenous vitamin C has been proposed to mitigate these effects, but strong evidence in patients with burn injury is lacking. OBJECTIVE: To evaluate the efficacy of high-dose intravenous vitamin C in patients with severe burn injury. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, placebo-controlled phase 3 trial conducted across 24 burn centers in North, Central, and South America; Europe; and Asia. Adults (≥18 years) with deep second- and/or third-degree burns covering 20% or more of total body surface area and requiring skin grafting were enrolled between August 18, 2020, and September 12, 2025. Final follow-up was completed in March 2026. The trial was stopped early after the first prespecified interim analysis for futility/harm. INTERVENTIONS: Patients were randomly assigned (1:1) to receive intravenous vitamin C (50 mg/kg every 6 hours for 96 hours) or matched placebo. MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of 28-day mortality and persistent organ dysfunction (defined as dependence on mechanical ventilation, kidney replacement therapy, or vasopressor/inotrope support at day 28). The main secondary outcome was time to discharge alive from hospital within 90 days. RESULTS: Among 238 patients enrolled (mean age, 48.9 [SD, 19.1] years; 79% male; mean total body surface area, 37.0% [SD, 14.6%]), 120 were assigned to vitamin C and 118 to placebo. The primary composite outcome occurred in 49 patients (40.8%) in the vitamin C group and 35 patients (29.7%) in the placebo group (adjusted risk ratio [RR], 1.28 [95% CI, 0.99-1.65]; P = .06), crossing the prespecified futility/harm threshold and prompting early trial termination. Time to discharge alive from hospital within 90 days was not improved (adjusted subdistribution hazard ratio, 0.85 [95% CI, 0.62-1.16]; P = .31). Twenty-eight-day mortality was higher in the vitamin C group (15.0% vs 7.6%; adjusted RR, 1.96 [95% CI, 1.32-2.90]; P = .001), as was hospital mortality (23.3% vs 16.1%; adjusted RR, 1.44 [95% CI, 1.03-2.00]; P = .03). CONCLUSIONS AND RELEVANCE: Among patients with severe burn injury, high-dose intravenous vitamin C did not reduce 28-day mortality and persistent organ dysfunction and is possibly harmful. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04138394.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Stoppe C, Hill A, Cancio LC, et al. High-Dose Intravenous Vitamin C and Mortality and Organ Dysfunction in Severe Burn Injury: The VICTORY Randomized Clinical Trial. JAMA. 2026. PMID: 42267875. doi:10.1001/jama.2026.10616

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。